Trial Profile
Phase IIb Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Tenofovir+Emtricitabine+Raltegravir or to Lamivudine+Abacavir+Raltegravir in Patients With Optimal Virological Control and Toxicity to the Current Combined Antiretroviral Regimen.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms RaSTA
- 15 Oct 2011 Subcutaneous fat and bone results presented at the 13th European AIDS Conference.
- 15 Oct 2011 Results presented at the 13th European AIDS Conference.
- 20 Jul 2011 Interim results presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.